Respiratory Tract Diseases

568 trials 207 recruiting

Filter these 568 trials by phase, country and sponsor.

Open in Search →

A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients with Muco-Obstructive Lung Dise… Ended

2024-514809-67-00 Asthma and Chronic obstructive pulmonary disease 9 2023-06-21
Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Ended

2024-512554-15-00 COVID-19 5 2023-06-21
Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients with Inflammatory Lung Disease Ended

2023-509654-60-00 Inflammatory Lung Disease 9 2023-06-21
A Single Dose, Fast State, Bioequivalence Study of CEFIXIMA ATB 400 mg Hard Capsules (Antibiotice S.A.) vs. CEFIXORAL® 400 mg Film Coated Ta… Ended

2023-504011-33-00 healthy subjects 2 2023-06-12
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who are Healthy Volunteers Co-administered the Medicine Ro… Ended

2023-503570-20-00 coronavirus disease 2019 (COVID-19) 3 2023-06-02
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tab… Ended

2022-502814-99-00 Non-small cell lung cancer (NSCLC) 2 2023-05-30
A study in healthy men to test how BI 1291583 is processed in the body Ended

2022-502264-20-00 Healthy 3 2023-04-26
A study of efficacy and safety of various treatments in participants with idiopathic pulmonary fibrosis (IPF) Ended

2023-508729-28-00 Idiopathic pulmonary fibrosis 4 2023-04-25
A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma (EXHALE-4) Ended

2023-509739-22-00 Eosinophilic asthma 5 2023-04-25
A 52-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-2) Ended

2023-507665-25-00 Severe Eosinophilic asthma 5 2023-04-25
A study to evaluate the effects of Treprostinil Palmitil Inhalation Powder in participants with Pulmonary Hypertension with Interstitial Lun… Ended

2023-505540-19-00 Pulmonary Hypertension Associated with Interstitial Lun 10 2023-04-24
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twel… Ended

2023-509243-27-00 Moderate-to-Severe Uncontrolled Asthma 4 2023-04-12
Evaluation of the value of 18F-Fluoromisonidazole (18F-FMISO) positron emission tomography hypoxia imaging in idiopathic pulmonary fibrosis … Ended

2024-515303-19-00 idiopathic pulmonary fibrosis 3 2023-03-20
The effect of oral folinic acid to prevent pemetrexed induced adverse events. Ended

2022-502345-10-00 Non small cell lung cancer (NSCLC), Mesothelioma, Thymo 6 2023-02-05
A study to learn how well the drug EDP-938 works and how safe it is for non-hospitalized Adults with Acute Respiratory Syncytial Virus Infec… Ended

2024-513861-38-00 Respiratory syncytial virus (RSV) 4 2023-02-02
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects … Ended

2024-514761-19-00 Idiopathic Pulmonary Fibrosis 5 2023-01-25
Dose ranging study of amlitelimab in adult participants with moderate-to-severe asthma Ended

2024-510641-33-00 Asthma 4 2023-01-17
Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE Ended

2022-501029-19-00 Asthma 6 2022-12-13
Long-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease Ended

2024-514602-31-00 aspirin-exacerbated respiratory disease 10 2022-12-07
Phase 2, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as additional therapy … Ended

2024-512621-88-00 Acute Respiratory Distress Syndrome 4 2022-12-06
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment … Ended

2022-500774-34-00 Urticaria 3 2022-11-08
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment co… Ended

2022-500775-31-00 Allergic rhinitis 3 2022-11-08
A study to test trimodulin in adult hospitalized patients with CAP including COVID-19 pneumonia. Ended

2024-513002-60-00 Non-severe community-acquired pneumonia (CAP) or modera 5 2022-10-26